ArticleScientific reports2026
Development and validation of pathomics signature for predicting prognosis of advanced high-grade serous ovarian carcinoma patients after platinum-based chemotherapy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In patients with advanced high-grade serous ovarian carcinoma (HGSOC), the standard treatment typically involves platinum-based chemotherapy after debulking surgery. However, the prognosis of patients following platinum-based chemotherapy varies, and known prognostic factors do not fully explain this variability. Therefore, developing an accurate and validated prognostic tool is essential. This study retrospectively analyzed hematoxylin and eosin (H&E) staining whole-slide images (WSIs) from 392 advanced HGSOC patients. A pathomics signature (PS) was developed and validated using pathomics features derived from the best model in an integrated machine learning framework. Discrimination performance was quantified using time-dependent 5-year receiver operating characteristic (ROC) curves. Calibration curves were also generated to compare predicted survival probabilities with actual outcomes. Genomic analysis was performed to elucidate the molecular mechanisms underlying the model's predictions. PS demonstrated significant risk stratification for overall survival and successfully identified patients likely to benefit from platinum-based chemotherapy. The predictive power of PS was validated in an external validation cohort. Furthermore, genomic analysis suggested that PS is influenced by the cytoskeleton, protein digestion and absorption pathways, and is correlated with immune cell infiltration, which may help predict the prognosis of advanced HGSOC patients after platinum-based chemotherapy. PS based on pathomics features is a potential prognostic marker for advanced HGSOC patients after platinum-based chemotherapy. This marker demonstrates robust prognostic ability and broad applicability. Further prospective studies are needed to assess the practical application of this model in precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.